TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment

Condition(s) targeted: Tuberculosis

Intervention: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol) (Drug); moxifloxacin (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: Centers for Disease Control and Prevention

Official(s) and/or principal investigator(s):
Richard E Chaisson, MD, Study Chair, Affiliation: Johns Hopkins University
Susan E Dorman, MD, Principal Investigator, Affiliation: Johns Hopkins University
John L Johnson, MD, Principal Investigator, Affiliation: Case Western Reserve University

This double-blind, randomized controlled trial evaluates moxifloxacin versus isoniazid in daily treatment during the first two months of treatment with rifampin, pyrazinamide and ethambutol for sputum smear-positive pulmonary tuberculosis.

Official title: TBTC Study 28: Evaluation of a Moxifloxacin-Based, Isoniazid-Sparing Regimen for Tuberculosis Treatment

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: • To compare the culture-conversion rate at the end of the intensive phase of therapy of the moxifloxacin regimen vs. that of the isoniazid regimen

Secondary outcome:

To compare the safety and tolerability of the moxifloxacin regimen to that of the isoniazid regimen

To determine the time to culture-conversion of the moxifloxacin regimen and the isoniazid regimen using data from 2-, 4-, 6-, and 8-week cultures

To compare the proportion of patients with any Grade 3 or 4 adverse reactions

To compare adverse events and 2-month culture conversion rates among HIV-infected patients vs. HIV-uninfected patients

To compare the rates of treatment failure of the moxifloxacin regimen and the isoniazid regimen

To determine whether there is delayed toxicity attributable to moxifloxacin (toxicity that becomes evident after the 8 weeks of moxifloxacin therapy)

Detailed description: The primary objective of this Phase 2 clinical trial is to compare the safety and antimicrobial activity of a moxifloxacin-containing regimen (moxifloxacin, rifampin, pyrazinamide, ethambutol [MRZE]) in which moxifloxacin has been substituted for isoniazid, to the standard control regimen (isoniazid, rifampin, pyrazinamide, ethambutol [HRZE]) in the first two months of treatment of sputum smear-positive pulmonary tuberculosis. The assessment of antimicrobial activity will be sputum culture-conversion. Higher rates of sputum culture conversion after 2 months of treatment with a moxifloxacin-containing regimen would support Phase 3 clinical trials of moxifloxacin in treatment regimens of less than the current 6 month standard regimens.

Rationale - Current treatment of smear positive pulmonary tuberculosis requires a minimum of

6 months, a treatment duration that is challenging for patients and tuberculosis control programs. Therefore, a high priority in tuberculosis research is the identification of agents that can shorten treatment. Several fluoroquinolone antibiotics have potent activity against Mycobacterium tuberculosis (M. tuberculosis) in preclinical testing. Of the currently available fluoroquinolones, moxifloxacin has excellent activity in vitro and in animal models of tuberculosis, a favorable pharmacokinetic profile (serum half-life of 10-12 hours), lack of problematic drug-drug interactions, no need for dosage adjustment for renal and hepatic insufficiency, and an excellent safety profile. In addition, in the murine model of tuberculosis, the substitution of moxifloxacin for isoniazid resulted in significant reductions in the time to culture conversion and the time to sterilization when compared to the standard combination rifampin, isoniazid and pyrazinamide. However, moxifloxacin has not been fully evaluated in humans for tuberculosis treatment. There is a need to assess not only the anti-tuberculosis activity of moxifloxacin-containing regimens, but also the safety of more prolonged therapy with moxifloxacin.

Two-month culture conversion rates are a well-accepted surrogate marker for the sterilizing activity of anti-tuberculosis drugs. Rifampin and pyrazinamide, the key drugs in current 6-month regimens, markedly increase 2-month culture-conversion rates. Therefore, this study will use 2-month culture conversion rate as the measure of antimicrobial activity of moxifloxacin.

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of

expectorated or induced sputum. Patients whose sputum cultures do not grow M. tuberculosis and those having an M. tuberculosis isolate resistant to (one or more) isoniazid, rifampin, fluoroquinolones, will be discontinued from the study, but followed for 14 days to detect late toxicities from study therapy. Patients having extra-pulmonary manifestations of tuberculosis, in addition to smear-positive pulmonary disease, are eligible for enrollment. Sputum must be expectorated or induced; smear results from respiratory secretions obtained by bronchoalveolar lavage or bronchial wash may not be used for assessment of study eligibility.

- Willingness to have HIV testing performed, if HIV serostatus is not known or if the

last documented negative HIV test was more than 6 months prior to enrollment. HIV testing does not need to be repeated if there is written documentation of a positive test (positive ELISA and Western Blot or a plasma HIV-RNA level greater than 5000 copies/ml) at any time in the past.

- 7 (seven) or fewer days of multidrug therapy for tuberculosis disease in the 6 months

preceding enrollment.

- 7 (seven) or fewer days of fluoroquinolone therapy in the 3 months preceding

enrollment.

- Age > 18 years

- Karnofsky score of at least 60 (requires occasional assistance but is able to care for

most of his/her needs; see Appendix B).

- Signed informed consent

- Women with child-bearing potential must agree to practice an adequate (barrier) method

of birth control or to abstain from heterosexual intercourse during study therapy.

- Laboratory parameters done at, or  14 days prior to, screening:

- Serum amino aspartate transferase (AST) activity ≤ 3 times the upper limit of normal

- Serum total bilirubin level ≤ 2. 5 times the upper limit of normal

- Serum creatinine level ≤ 2 times the upper limit of normal

- Complete blood count with hemoglobin level of at least 7. 0 g/dL

- Complete blood count with platelet count of at least 50,000/mm3

- Serum potassium > 3. 5 meq/L

- Negative pregnancy test (women of childbearing potential)

Exclusion Criteria:

- Breast-feeding

- Known intolerance to any of the study drugs

- Known allergy to any fluoroquinolone antibiotic

- Concomitant disorders or conditions for which moxifloxacin (MXF), isoniazid (INH),

rifampin (RIF), pyrazinamide (PZA), or ethambutol (EMB) are contraindicated. These include severe hepatic damage, acute liver disease of any cause, and acute uncontrolled gouty arthritis.

- Current or planned therapy during the intensive phase of therapy using drugs having

unacceptable interactions with rifampin (rifabutin can be substituted for rifampin during the continuation phase of therapy).

- Current or planned antiretroviral therapy during the intensive phase of therapy.

- History of prolonged QT syndrome or current or planned therapy with quinidine,

procainamide, amiodarone, sotalol, disopyramide, ziprasidone, or terfenadine during the intensive phase of therapy.

- Pulmonary silicosis

- Central nervous system TB

Hopital Universitario Clementino Fraga Filho, Rio de Janeiro 2194.590, Brazil

Agencia de Salut Publica, Barcelona 08023, Spain

Makerere University Medical School, Kampala, Uganda

Veterans Administration Medical Center of Arkansas, Little Rock, Arkansas 72205, United States

University of California at San Diego, San Diego, California 92103, United States

University of Southern California Medical Center, Los Angeles, California 90033, United States

University of California, San Francincisco, San Francisco, California 94110, United States

Denver Public Health Department, Denver, Colorado 80204, United States

Washington DC Veterans Administration Medical Center, Washington DC, District of Columbia 20422, United States

Emory University School of Medicine, Atlanta, Georgia 30303, United States

Hines Veterans Administration Medical Center, Hines, Illinois 60141, United States

Northwestern University, Chicago, Illinois 60611, United States

Nelson R. Mandela School of Medicine, Durban, KwaZulu Natal, South Africa

University of Manitoba, Winnepeg, Manitoba R3A 1R8, Canada

Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, United States

Boston University Medical Center, Boston, Massachusetts 02118, United States

New Jersey School of Medicine, Newark, New Jersey 07103, United States

Columbia University, New York, New York 10032, United States

Harlem Hospital, Columbia University, New York, New York 10037, United States

Duke University Medical Center, Durham, North Carolina 27710, United States

Montreal Chest Institute, Montreal, Quebec H2X 2P4, Canada

Veterans Administration Tennessee Valley Health Care System, Nashville, Tennessee 37232, United States

University of North Texas Health Science Center, Fort Worth, Texas 76104, United States

Houston Veterans Administration Medical Center, Houston, Texas 77030, United States

Audie L Murphy Memorial Veterans Administration Medical Center, San Antonio, Texas 78284, United States

Seattle-King County Health Department, Seattle, Washington 98104, United States

Starting date: February 2006
Ending date: December 2007
Last updated: September 20, 2007